( May 8, 2026, 8:10 AM EDT) -- SAN JOSE, Calif. — A federal judge in California granted final approval to a $7.25 million settlement in a case brought by investors against a biopharmaceutical company, certain of its executives and board members for alleged misstatements the defendants made regarding the risks associated with the Phase 3 clinical trial of the company’s lead drug candidate, which led to the company’s stock being artificially inflated....